Intratumoral heterogeneity in the self-renewal and tumorigenic differentiation of ovarian cancer

Stem Cells

Volumn 30, Issue 3, 2012, Pages 415-424

  Abelson, Sagi ^a   Shamai, Yeela ^a   Berger, Liron ^a   Shouval, Roni ^a   Skorecki, Karl ^a   Tzukerman, Maty ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cancer stem cell niche; Cancer stem cells; Human embryonic stem cells; Niche dependent self renewal capacity; Tumor microenvironment

Indexed keywords

ALDEHYDE DEHYDROGENASE; HERMES ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENICITY; CELL CLONE; CELL DIFFERENTIATION; CELL GROWTH; CELL HETEROGENEITY; CELL RENEWAL; CELL SUBPOPULATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD44; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; STEM CELL NICHE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84857485231     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1029     Document Type: Article

References (42)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
2. Marusyk A, Polyak K. Tumor heterogeneity: Causes and consequences. Biochim Biophys Acta 2010;1805:105-117.
3. Czernobilsky B, Silverman BB, Mikuta JJ. Endometrioid carcinoma of the ovary. A clinicopathologic study of 75 cases. Cancer 1970;26:1141-1152.
4. Montag AG, Jenison EL, Griffiths CT et al. Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int J Gynecol Pathol 1989;8:85-96. (Pubitemid 19116244)
5. Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: A continuing enigma. J Clin Pathol 2007;60:355-360. (Pubitemid 46596552)
6. Köbel M, Kalloger SE, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
7. DeLair D, Oliva E, Köbel M et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: A study of 155 cases. Am J Surg Pathol 2011;35:36-44.
8. Katz E, Skorecki K, Tzukerman M. Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations. Clin Cancer Res 2009;15:70-80.
9. Tzukerman M, Rosenberg T, Ravel Y et al. An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. Proc Natl Acad Sci USA 2003;100:13507-13512. (Pubitemid 37444772)
10. Tzukerman M, Rosenberg T, Reiter I et al. The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts. Cancer Res 2006;66:3792-3801.
11. Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene 2001;20:8085-8091. (Pubitemid 34028332)
12. Suo G, Han J, Wang X et al. Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun 2005;337:1047-1051. (Pubitemid 41505231)
13. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. (Pubitemid 36418143)
14. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-1037.
15. Patrawala L, Calhoun T, Schneider-Broussard R et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-1708.
16. Chan KS, Espinosa I, Chao M et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009;106:14016-14021.
17. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104:10158-10163. (Pubitemid 47175279)
18. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104: 973-978. (Pubitemid 46154721)
19. Ebben JD, Treisman DM, Zorniak M et al. The cancer stem cell paradigm: A new understanding of tumor development and treatment. Expert Opin Ther Targets 2010;14:621-632.
20. Zhang S, Balch C, Chan MW et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-4320.
21. Alvero AB, Chen R, Fu HH et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009;8:158-166.
22. Chute JP, Muramoto GG, Whitesides J et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 2006;103:11707-11712. (Pubitemid 44182515)
23. Pierre-Louis O, Clay D, Brunet de la Grange P et al. Dual SP/ALDH functionalities refine the human hematopoietic Lin-CD34+CD38- stem/progenitor cell compartment. Stem Cells 2009;27:2552-2562.
24. Muramoto GG, Russell JL, Safi R et al. Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. Stem Cells 2010;28:523-534.
25. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567. (Pubitemid 350056407)
26. Deng S, Yang X, Lassus H et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010;5:e10277.
27. Alison MR, Guppy NJ, Lim SM et al. Finding cancer stem cells: Are aldehyde dehydrogenases fit for purpose? J Pathol 2010;222:335-344.
28. Choi YP, Shim HS, Gao MQ et al. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett 2011;307:62-71.
29. Gosling J. HIV/aids: An encounter with death or a journey into life? J Anal Psychol 2008;53:261-269. (Pubitemid 351422414)
30. Campbell LL, Polyak K. Breast tumor heterogeneity: Cancer stem cells or clonal evolution? Cell Cycle 2007;6:2332-2338. (Pubitemid 350058682)
31. Shackleton M, Quintana E, Fearon ER et al. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell 2009;138:822-829.
32. Clarke MF, Fuller M. Stem cells and cancer: Two faces of eve. Cell 2006;124:1111-1115.
33. Polyak K, Hahn WC. Roots and stems: Stem cells in cancer. Nat Med 2006;12:296-300. (Pubitemid 43355075)
34. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
35. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009;324:1670-1673.
36. Borovski T, De Sousa E, Melo F et al. Cancer stem cell niche: The place to be. Cancer Res 2011;71:634-639.
37. Berry NB, Bapat SA. Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovarian Res 2008;1:8-19.
38. Clevers H. The cancer stem cell: Premises, promises and challenges. Nat Med 2011;17:313-319.
39. Chaffer CL, Brueckmann I, Scheel C et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011;108:7950-7955.
40. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598.
41. Quintana E, Shackleton M, Foster HR et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510-523.
42. Kajihara H, Yamada Y, Kanayama S et al. Clear cell carcinoma of the ovary: Potential pathogenic mechanisms. Oncol Rep 2010;23:1193-1203.